Targeted drug delivery technology takes a step forward with Suono Bio’s exclusive patent option agreement for the first-in-kind “RoboCap” electromechanical oral drug delivery pill.
With the agreement, granted by Massachusetts Institute of Technology, the MTVP portfolio company secured exclusive rights for the RoboCap IP, which includes the design and methods to transiently displace the mucus layer throughout the lower GI tract to facilitate improved absorption of drugs beyond small molecules, such as mRNA-based oral medicines.
This agreement bolsters Suono Bio’s oral drug delivery program, adding to their existing ultrasound-mediated drug delivery technology that recently achieved positive results for a First-in-Human study in the GI tract.
Read the press release here.